J&J wins approval for first-of-its-kind psoriasis pill

Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could roil a multibillion-dollar market.

The drug, Icotyde, is approved for patients over the age of 12 with moderate to severe plaque psoriasis, J&J said Wednesday. Developed as icotrokinra, Icotyde is designed to mimic the effects of top-selling psoriasis treatments, including AbbVie's Skyrizi and J&J's own Tremfya, without the need for needles.